

language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications and/or contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Board of Regents of the National Library of Medicine.

Date: February 27–28, 2001.

Open: February 27, 2001, 9:00 am to 4:40 pm.

Agenda: Administrative Reports and Program Discussion.

Place: National Library of Medicine, Board Room, Bldg 38, 2E–09, 8600 Rockville Pike, Bethesda, MD 20894.

Closed: February 27, 2001, 4:40 pm to 5:00 pm.

Agenda: To review and evaluate grant applications.

Place: National Library of Medicine, Board Room, Bldg 38, 2E–09, 8600 Rockville Pike, Bethesda, MD 20894.

Open: February 28, 2001, 9:15 am to 11:30 am.

Agenda: Administrative Reports and Program Discussion.

Place: National Library of Medicine, Board Room, Bldg 38, 2E–09, 8600 Rockville Pike, Bethesda, MD 20894.

Contact Person: Donald A.B. Lindberg, MD, Director, National Library of Medicine, National Institutes of Health, PHS, DHHS, Bldg 38, Room 2E17B, Bethesda, MD 20894. (Catalogue of Federal Domestic Assistance Program Nos. 93.879, Medical Library Assistance, National Institutes of Health, HHS)

Dated: January 9, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 01–1458 Filed 1–17–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License: Method for Preparing 17 α -Acetoxy-11 β -(4-,N-Dimethylaminophyl)-19-Norpregna-4, 9-Diene-3,20-Dione, Intermediates Useful in the Method, and Methods for the Preparation of Such Intermediates

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive license worldwide to practice the invention embodied in: U.S. Patent Application Serial No. 08/413,755, filed March 30, 1995, issuing as U.S. Patent 5,929,262 entitled, “Method for Preparing 17 α -Acetoxy-11 β -(4-N,N-Dimethylaminophyl)-19-Norpregna-4, 9-Diene-3,20-Dione, Intermediates Useful in the Method, and Methods for the Preparation of such Intermediates” to HRA Pharma, a corporation of France, having a place of business in Paris, France. The patent rights in this invention have been assigned to the United States of America, as represented by the Department of Health and Human Services.

DATES: Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before April 18, 2001 will be considered.

ADDRESSES: Requests for a copy of the patent applications, inquiries, comments and other materials relating to the contemplated license should be directed to: Dennis H. Penn, Pharm.D., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Telephone: (301) 496–7056, ext. 211; Facsimile: (301) 402–0220.

SUPPLEMENTARY INFORMATION: In an effort to develop an efficacious treatment for human reproductive disorders this invention describes methods for the synthesis of 17 α -Acetoxy-11 β -(4-N,N-Dimethylaminophyl)-19-Norpregna-4,9-Diene-3,20-Dione Intermediates Useful in the Method, and Methods for the Preparation of such Intermediates This compound may have utility in treating

human reproductive disorders and hormone sensitive tumors.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 90 days from the date of this published Notice, NIH received written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

The field of use may be limited to the use of the invention for the synthesis 17 α -Acetoxy-11 β -(4-N,N-Dimethylaminophyl)-19-Norpregna-4, 9-Diene-3,20-Dione and intermediates useful in the method of synthesis and preparation of such intermediates.

Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: January 8, 2001.

Jack Spiegel,

Director, Division of Technology Development and Transfer, Office of Technology Transfer.

[FR Doc. 01–1465 Filed 1–17–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License: Orally Active Derivatives of 1,3,5(10)-Estratriene

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive license worldwide to practice the invention embodied in: U.S. Patent Application Series No. 08/122,853, filed September 17, 1993, issuing as U.S. Patent 5,554,603 on September 10, 1996 entitled, “Orally Active Derivatives of 1,3,5(10)-Estratriene” to the R.W. Johnson Pharmaceutical Research Institute, a corporation of Delaware, having a place of business in Raritan, New Jersey. The patent rights in this invention have been assigned to the

United States of America, as represented by the Department of Health and Human Services.

DATES: Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before March 19, 2001 will be considered.

ADDRESSES: Requests for a copy of the patent applications, inquiries, comments and other materials relating to the contemplated license should be directed to: Dennis H. Penn, Pharm.D., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: (301) 496-7056, ext. 211; Facsimile: (301) 402-0220.

SUPPLEMENTARY INFORMATION: In an effort to develop an efficacious treatment for human reproductive disorders this invention describes orally active derivatives of 1,3,5(10)-estratriene. This compound may have utility as a contraceptive and as an estrogen replacement for the treatment and prevention of postmenopausal conditions.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 60 days from the date of this published Notice, NIH received written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

The field of use may be limited to the use of the invention for the development of pharmaceutical compounds for use as a contraceptive and for treatment and prevention of postmenopausal conditions.

Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: January 8, 2001.

Jack Spiegel,

Director, Division of Technology Development and Transfer, Office of Technology Transfer.
[FR Doc. 01-1464 Filed 1-17-01; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License: Prophylactic and/or Therapeutic Vaccine Against Pseudomonas Aeruginosa, Chlamydia, Trachomatis and Mycoplasma Pneumonia

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice in accordance with 15 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a limited field of use exclusive worldwide license to practice the inventions embodied in U.S. Serial Number 09/462,682, filed January 10, 2000 (claiming priority to U.S. Provisional Patent Application Serial No. 60/052,375, filed July 11, 1997), entitled "Pseudomonas exotoxin A-Like Chimeric Immunogens" and U.S. Serial Number 09/462,713 filed May 12, 2000 (claiming priority to U.S. Provisional Patent Application Serial No. 60/056,924, filed July 11, 1997), entitled "Pseudomonas Exotoxin A-like Chimera Immunogens for eliciting a secretory IgA-Mediated Immune Response" to Trinity BioSystems, L.L.C. of Los Altos Hills, California, U.S.A. The United States as represented by the Department of Health and Human Services is an assignee of these patent rights.

DATES: Only written comments and/or applications for a license which are received by NIH on or before March 19, 2001 will be considered.

ADDRESSES: Requests for a copy of these patent applications, inquiries, comments, and other materials relating to the contemplated license should be directed to: Carol A. Salata, Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: (301) 496-7735 ext. 232; Facsimile: (301) 402-0220; E-mail: salatac@OD.NIH.GOV. A signed Confidential Disclosure Agreement (CDA) may be required to receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: The patent applications describe the use of Pseudomonas exotoxin A-like chimeric immunogens in which a non-native epitope is inserted into a domain. These immunogens are useful to elicit humoral, cell-mediated and mucosal

immune responses against the non-native epitope.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.

It is anticipated that this license may be limited to the field of use as a prophylactic and/or therapeutic vaccine against Pseudomonas aeruginosa, Chlamydia trachomatis and Mycoplasma pneumoniae. Trinity BioSystems will use Pseudomonas exotoxin A to target and deliver pathogen peptide epitopes wherein said pathogen peptide epitopes are inserted into or replace a domain of Pseudomonas exotoxin A.

This prospective exclusive license may be granted unless within 60 days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Applications for a license filed in response to this notice will be treated as objections to the grant of the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: January 8, 2001.

Jack Spiegel,

Director, Division of Technology Development and Transfer, Office of Technology Transfer.
[FR Doc. 01-1463 Filed 1-17-01; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Office for Women's Services; Notice of Meeting

Pursuant to Public Law 92-463, notice is hereby given of the meeting of the Advisory Committee for Women's Services of the Substance Abuse and Mental Health Services Administration (SAMHSA) on Friday January 26, 2001.

The meeting of the Advisory Committee for Women's Services will include a discussion of policy and program issues relating to women's substance abuse and mental health service needs; the SAMHSA fiscal year 2001 budget; specific Committee goals for the current year, planning discussions for SAMHSA's Third National Conference on Women,